Autoimmune disease companies develop therapies, diagnostics and research technologies for conditions in which the immune system attacks the body’s own cells and tissues. Their work spans disease detection, immune modulation and the development of more targeted treatments.
This category includes companies working on:
Browse 68 UK autoimmune disease companies below.
Gene therapy immune regulators for infection, cancer and autoimmunity
Virothera develops gene therapies intended to regulate immune responses in persistent diseases. Its approach draws on human versions of immune-modifying proteins that viruses have evolved to influence immune cells. The company aims to use these proteins to create targeted treatments with potential advantages over some…
Specialty biopharma covering oncology, neurology, and fertility
Merck Serono Limited is the UK commercial subsidiary of Merck KGaA's Healthcare division, a German science and technology company founded in 1668. The UK operation markets prescription medicines across oncology, neurology, immunology, endocrinology, and fertility. Key products include Erbitux for colorectal and…
Native mass spectrometry platform for small molecule drug discovery
OMass Therapeutics is a biotechnology company developing small molecule therapeutics against membrane proteins, GPCRs, and intracellular complexes that have historically been difficult to drug. Its proprietary platform combines native mass spectrometry, novel biochemistry, and custom chemistry to interrogate protein…
Single-cell genomics and AI platform for autoimmune and fibrotic disease
Ensocell is a Cambridge-based biotechnology company developing precision biologics for autoimmune, inflammatory, and fibrotic diseases. Its platform integrates single-cell and spatial genomics with AI-based computational tools and advanced cell models to identify novel disease intervention points and design targeted…
Clinical-stage biopharma developing treatments for cancer and rare diseases
Biodexa Pharmaceuticals is a Cardiff-based clinical-stage biopharmaceutical company advancing a pipeline of proprietary drug formulations for diseases with high unmet need. Its lead programme, eRapa, an encapsulated oral formulation of rapamycin, is in a Phase 3 registrational trial for familial adenomatous polyposis,…
Dendritic cell biology platform for cancer and autoimmune therapies
Adendra Therapeutics is a discovery-stage biotechnology company developing small molecule and biologic medicines targeting dendritic cell biology for the treatment of solid tumours and autoimmune diseases. The company's approach is based on research into how dendritic cells regulate adaptive immune responses to cell…
Human proteome microarrays and protein array screening services
Cambridge Protein Arrays supplies human proteome microarrays and specialist screening services for researchers. Its HuProt arrays contain thousands of full-length human proteins, enabling antibody specificity testing, autoantibody profiling and investigations of molecular interactions. Researchers can obtain arrays or…
Biotech venture builder co-creating and scaling drug discovery companies
Molecule to Medicine (MTM) is a biotech venture builder that co-creates, builds, and scales drug discovery companies within a shared operational ecosystem, combining drug discovery expertise with shared infrastructure to enable rapid company formation. UK operations are based at Milton Park, Abingdon, with a further…
Intestinal barrier repair therapies for inflammatory bowel disease
Thelior Bio is a University of Oxford spin-out developing therapies for inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Its research focuses on restoring the intestinal epithelial barrier, addressing impaired tissue repair associated with chronic inflammation. The company draws on…
T cell immunotherapies for infectious disease, cancer and autoimmunity
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific T cell immunotherapies for chronic infectious diseases, autoimmune conditions, and cancer. Its pipeline is built on four proprietary viral vector and synthetic immunotherapy platforms and includes clinical candidates…
Targeted antibody therapeutics for cancer and autoimmune disease
Medannex is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics targeting annexin-A1, a protein implicated in cancer progression, autoimmunity, and inflammation. Its lead asset, MDX-124, is the first therapeutic antibody to target annexin-A1 and is currently being evaluated in the…
Specialist immunology CRO for preclinical biotherapeutic drug discovery
RoukenBio is a specialist contract research organisation providing preclinical immunology services to biopharmaceutical companies worldwide. Its team offers cell-based bioassay development, functional characterisation of antibody therapeutics and complex biologics, cell line engineering, and CMC-quality potency assay…
Biologic therapies for autoinflammatory and autoimmune diseases
Kiniksa Pharmaceuticals International is a commercial-stage biopharmaceutical company focused on acquiring, developing and commercialising medicines for autoinflammatory and autoimmune diseases with significant unmet need. Its approved product, rilonacept, is an IL-1 inhibitor indicated for recurrent pericarditis. The…
Immunology CRO for immuno-oncology, autoimmunity and inflammation
Celentyx is a contract research organisation providing bespoke assay services in human immunology to pharmaceutical and biotechnology clients. Operating from sites in Birmingham and Oxford, the company uses primary human cells and tissues from healthy donors and patients to support drug discovery across…
Multispecific immune cell engagers targeting gamma delta T cells
Cytospire Therapeutics is developing multispecific engager antibodies designed to enhance and direct the activity of gamma delta T cells for the treatment of cancer and autoimmune disease. The company emerged from stealth in 2024, backed by Abingworth, 4BIO Capital and LifeArc Ventures. Its platform targets both…
Probiotic microbiome platform for skin health and dermatological conditions
SkinBioTherapeutics is a biotechnology company developing microbiome-based technologies for skin health. Its proprietary platform harnesses lysates derived from probiotic bacteria to improve skin barrier function, reduce infection risk, and support wound healing. Programmes target cosmetic skincare, psoriasis, eczema,…
TCR-based bispecific therapeutics for cancer and autoimmune disease
T-Therapeutics is a biotechnology company developing T cell receptor-based therapeutics for cancer and autoimmune disease. Using a humanised TCR mouse platform to generate high-affinity, antigen-specific human T cell receptors, the company engineers bispecific molecules that redirect a patient's own T cells to…
Neuroimaging contract research organisation for clinical trial biomarker analysis
IXICO is a London-based imaging contract research organisation providing end-to-end neuroimaging services to biopharmaceutical companies conducting clinical trials in neurological diseases. The company collects, manages, and analyses MRI, PET, and SPECT imaging data from global trial sites, generating AI-driven…
Programmable iPSC cell therapies for cancer and autoimmunity
Xap Therapeutics is a Cambridge-based biotechnology company developing a synthetic biology platform for next-generation cell therapeutics. The company applies CRISPR technology to engineer induced pluripotent stem cells (iPSCs) into a universal "chassis" cell that can be functionalised with engineered receptors and…
Oral delivery platform for biologics targeting inflammatory diseases
Intract Pharma is a biotechnology company developing proprietary formulation platforms for the oral delivery of complex biologics including monoclonal antibodies and proteins. The technology enables precision delivery to the colon for local and systemic immunomodulation, targeting gastrointestinal and systemic…